Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat in Hepatic Impairment
NCT07049939Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bomedemstat in Myeloproliferative Neoplasm (MPN), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity at 216 hours and Maximum Plasma Concentration at 216 hours. Started Aug 2025; status: completed.
02
Drugs
bomedemstat
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07049939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049939.